|
Apr 9
|
AbbVie’s upadacitinib gains EU marketing authorisation for GCA
|
|
Apr 8
|
AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis
|
|
Apr 8
|
Goldman turns cautious on major pharma names, sees select upside at Eli Lilly
|
|
Apr 8
|
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
|
|
Apr 8
|
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
|
|
Apr 7
|
AbbVie (NYSE:ABBV) Showcases Cancer Treatment Advancements at AACR Annual Meeting
|
|
Feb 17
|
Why AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now
|
|
Feb 16
|
AbbVie Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 15
|
Is AbbVie Stock a Buy Now?
|
|
Feb 14
|
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
|
|
Feb 14
|
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
|
|
Feb 13
|
AbbVie Declares Quarterly Dividend
|
|
Feb 13
|
AbbVie Inc. (ABBV): Among Lee Munder Capital Group’s Top Stock Picks
|
|
Feb 13
|
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
|
|
Feb 13
|
Is AbbVie Inc. (NYSE:ABBV) Trading At A 47% Discount?
|
|
Feb 13
|
AbbVie and Xilio to collaborate on antibody-based immunotherapies
|
|
Feb 12
|
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
|
|
Feb 12
|
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
|
|
Feb 12
|
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
|
|
Feb 11
|
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
|